Stock OBJ OBJ LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials OBJ Limited Australian S.E.

Equities

OBJ

AU0000077463

Biotechnology & Medical Research

End-of-day quote Australian S.E.
Other stock markets
 		5-day change 1st Jan Change
- AUD -.--% Intraday chart for OBJ Limited -.--% -.--%
Apr. 08 Wellfully Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Feb. 29 Wellfully Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 50.66 25.33 27.14 10.49 14.07 1.479
Enterprise Value (EV) 1 46.73 23.33 27.57 8.029 14.24 1.521
P/E ratio -29.7 x -14.8 x -7.31 x -1.22 x -1.7 x -0.18 x
Yield - - - - - -
Capitalization / Revenue 24.8 x 9.23 x 18.3 x 8.72 x 5.34 x 0.98 x
EV / Revenue 22.9 x 8.5 x 18.6 x 6.67 x 5.4 x 1.01 x
EV / EBITDA -29.1 x -14.6 x -8.05 x -1.35 x -1.81 x -0.23 x
EV / FCF -55.7 x -18.2 x -35.4 x -2.54 x -2.67 x -3.48 x
FCF Yield -1.8% -5.49% -2.82% -39.4% -37.4% -28.7%
Price to Book 11.9 x 9.95 x -22.3 x 4.54 x 22.7 x -0.86 x
Nbr of stocks (in thousands) 90,473 90,473 90,473 209,820 270,560 492,944
Reference price 2 0.5600 0.2800 0.3000 0.0500 0.0520 0.003000
Announcement Date 9/14/18 9/27/19 9/30/20 9/30/21 10/2/22 2/29/24
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 2.04 2.745 1.484 1.203 2.635 1.508
EBITDA 1 -1.606 -1.597 -3.425 -5.958 -7.852 -6.479
EBIT 1 -1.703 -1.67 -3.499 -5.99 -7.872 -6.5
Operating Margin -83.47% -60.83% -235.72% -497.78% -298.75% -431.08%
Earnings before Tax (EBT) 1 -1.699 -1.71 -3.713 -6.397 -7.303 -6.355
Net income 1 -1.699 -1.71 -3.713 -6.397 -7.303 -6.355
Net margin -83.27% -62.3% -250.17% -531.62% -277.14% -421.46%
EPS 2 -0.0189 -0.0189 -0.0410 -0.0410 -0.0306 -0.0171
Free Cash Flow 1 -0.8393 -1.28 -0.7779 -3.163 -5.329 -0.4371
FCF margin -41.14% -46.65% -52.41% -262.85% -202.22% -28.99%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/14/18 9/27/19 9/30/20 9/30/21 10/2/22 2/29/24
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 0.43 - 0.17 0.04
Net Cash position 1 3.94 2 - 2.46 - -
Leverage (Debt/EBITDA) - - -0.1263 x - -0.022 x -0.006468 x
Free Cash Flow 1 -0.84 -1.28 -0.78 -3.16 -5.33 -0.44
ROE (net income / shareholders' equity) -34.1% -50.3% -560% -1,174% -499% 1,165%
ROA (Net income/ Total Assets) -19.3% -26.3% -101% -163% -164% -133%
Assets 1 8.789 6.508 3.675 3.916 4.462 4.776
Book Value Per Share 2 0.0500 0.0300 -0.0100 0.0100 0 -0
Cash Flow per Share 2 0.0500 0.0200 0.0100 0.0100 0 0
Capex 1 0.04 0.02 - 0.06 0.03 0.11
Capex / Sales 1.95% 0.78% - 5.38% 1.23% 7.07%
Announcement Date 9/14/18 9/27/19 9/30/20 9/30/21 10/2/22 2/29/24
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+46.51% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.57% 11.95B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 11.32B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. WFL Stock
  4. OBJ Stock
  5. Financials OBJ Limited